Congress logo
Back to Conference page

UICC World Cancer Congress 2006

Bridging the Gap: Transforming Knowledge into Action

July 8-12, 2006, Washington, DC, USA



Monday, 10 July 2006 - 12:00 PM
84-90

Radiotherapy in the Treatment of Patients with Regional Metastases of Hypopharyngeal Cancer

Viacheslav LYUBAEV, MD, PhD, DSc1, Aizhana AIDARBEKOVA, MD, PhD1, Somasundaram SUBRAMANIAN, MD1, Sergei Tkachev, MD, PhD, DSc2, and Sevil Alieva, MD, PhD2. (1) Head & Neck Surgery, N.N. Blokhin Russian Cancer Research Center, 24, Kashirskoye Shosse, Moscow, 115478, Russia, (2) Division of Radiation Oncology, N.N. Blokhin Russian Cancer Research Center, 24, Kashirskoye Shosse, Moscow, 115478, Russia

Objective: To analyze the efficacy of radiotherapy in patients with regional metastases of hypopharyngeal cancer.

Methods: From 1981 to 2000 radiotherapy was performed in 27 patients with hypopharyngeal cancer at N.N. Blokhin Russian Cancer Research Center. The mean age of the patients was 57 years. In 12 (44.44%) patients metastases were found in level II; in 1 (3.7%) patient in level III, in 4 (14.81%) patients – in levels II & III, in 2 (7.41%) patients – in levels III & IV, in 7 (25.94%) – in levels II to IV and in 1 (3.7%) patient – in levels II to V. None of the patients had level I to VI involved. As per TNM classification, 8 patients had N1, 6 had N2 and 13 had N3 disease. All patients had neck metastases in the same side of lesion and in six patients the contralateral side was also involved. In 10 (37.04%) the metastases were mobile, in 4 (14.81%) patients - partially mobile and in 13 (48.15%) patients they were fixed.

Results: All patients underwent only radiotherapy. Total regression or 75% regression was achieved in 5 (18.52%) out of 27 patients. Partial effect was observed in 11 (40.74%) patients. Less than 25% or no effect was observed in 10 (37.04%) patients. In one (3.7%) patient progression of disease was registered during treatment. 5-year survival was 11.2+6.05%.

Conclusion: Radiotherapy as a single modality is effective for metastases less than 3 cm in level II , single lesion and exophytic or endophytic growth of primary tumor.


See more of Cancer Research, Detection and Treatment
See more of Cancer Research, Detection and Treatment

See more of The UICC World Cancer Congress 2006